Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 2/2018

01-02-2018 | Original Article

Breathing-motion-compensated robotic guided stereotactic body radiation therapy

Patterns of failure analysis

Authors: Susanne Stera, MD, Panagiotis Balermpas, MD, Mark K. H. Chan, PhD, Stefan Huttenlocher, MD, Stefan Wurster, MD, Christian Keller, MD, Detlef Imhoff, Dirk Rades, MD, Jürgen Dunst, MD, Claus Rödel, MD, Guido Hildebrandt, MD, Oliver Blanck, PhD

Published in: Strahlentherapie und Onkologie | Issue 2/2018

Login to get access

Abstract

Purpose

We retrospectively evaluated the patterns of failure for robotic guided real-time breathing-motion-compensated (BMC) stereotactic body radiation therapy (SBRT) in the treatment of tumors in moving organs.

Patients and methods

Between 2011 and 2016, a total of 198 patients with 280 lung, liver, and abdominal tumors were treated with BMC-SBRT. The median gross tumor volume (GTV) was 12.3 cc (0.1–372.0 cc). Medians of mean GTV BEDα/β = 10 Gy (BED = biological effective dose) was 148.5 Gy10 (31.5–233.3 Gy10) and prescribed planning target volume (PTV) BEDα/β = 10 Gy was 89.7 Gy10 (28.8–151.2 Gy10), respectively. We analyzed overall survival (OS) and local control (LC) based on various factors, including BEDs with α/β ratios of 15 Gy (lung metastases), 21 Gy (primary lung tumors), and 27 Gy (liver metastases).

Results

Median follow-up was 10.4 months (2.0–59.0 months). The 2‑year actuarial LC was 100 and 86.4% for primary early and advanced stage lung tumors, respectively, 100% for lung metastases, 82.2% for liver metastases, and 90% for extrapulmonary extrahepatic metastases. The 2‑year OS rate was 47.9% for all patients. In uni- and multivariate analysis, comparatively lower PTV prescription dose (equivalence of 3 × 12–13 Gy) and higher average GTV dose (equivalence of 3 × 18 Gy) to current practice were significantly associated with LC. For OS, Karnofsky performance score (100%), gender (female), and SBRT without simultaneous chemotherapy were significant prognostic factors. Grade 3 side effects were rare (0.5%).

Conclusions

Robotic guided BMC-SBRT can be considered a safe and effective treatment for solid tumors in moving organs. To reach sufficient local control rates, high average GTV doses are necessary. Further prospective studies are warranted to evaluate these points.
Literature
1.
Guckenberger M, Allgäuer M, Appold S et al (2013) Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol 8(8):1050–1058CrossRefPubMed
2.
Guckenberger M, Andratschke N, Alheit H et al (2014) Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol 190(1):26–33CrossRefPubMed
3.
Davis JN, Medbery C 3rd, Sharma S et al (2015) Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry. J Radiat Oncol 4(1):55–63CrossRefPubMedPubMedCentral
4.
5.
Rieber J, Streblow J, Uhlmann L et al (2016) Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases – A pooled analysis of the German working group “stereotactic radiotherapy”. Lung Cancer 97:51–58CrossRefPubMed
6.
7.
Ricco A, Davis J, Rate W et al (2017) Lung metastases treated with stereotactic body radiotherapy: the RSSearch® patient Registry’s experience. Radiat Oncol 12(1):35–31CrossRefPubMedPubMedCentral
8.
Sterzing F, Brunner TB, Ernst I et al (2014) Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 190(10):872–881CrossRefPubMed
9.
Vautravers-Dewas C, Dewas S, Bonodeau F et al (2011) Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship? Int J Radiat Oncol Biol Phys 81(3):e39–e47CrossRefPubMed
10.
Andratschke N, Parys A, Stadtfeld S et al (2016) Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases. Radiat Oncol 11:74CrossRefPubMedPubMedCentral
11.
12.
Nuyttens JJ, Prevost JB, Van der Voort van Zijp NC et al (2007) Curative stereotactic robotic radiotherapy treatment for extracranial, extrapulmonary, extrahepatic, and extraspinal tumors: technique, early results, and toxicity. Technol Cancer Res Treat 6(6):605–610CrossRefPubMed
13.
Casamassima F, Livi L, Masciullo S et al (2012) Stereotactic radiotherapy for adrenal gland metastases: university of Florence experience. Int J Radiat Oncol Biol Phys 1;82(2):919–923CrossRef
14.
15.
Liu F, Tai A, Lee P et al (2017) Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models. Radiother Oncol 122(2):286–294CrossRefPubMed
16.
17.
Kilby W, Dooley JR, Kuduvalli G et al (2010) The CyberKnife Robotic Radiosurgery System in 2010. Technol Cancer Res Treat 9(5):433–452CrossRefPubMed
18.
Schweikard A, Shiomi H, Adler J (2004) Respiration tracking in radiosurgery. Med Phys 31(10):2738–2741CrossRefPubMed
19.
Pepin EW, Wu H, Zhang Y et al (2011) Correlation and prediction uncertainties in the cyberknife synchrony respiratory tracking system. Med Phys 38(7):4036–4044CrossRefPubMedPubMedCentral
20.
Chan MK, Werner R, Ayadi M et al (2015) Comparison of 3D and 4D Monte Carlo optimization in robotic tracking stereotactic body radiotherapy of lung cancer. Strahlenther Onkol 191(2):161–171CrossRefPubMed
21.
Chan M, Grehn M, Cremers F et al (2017) Dosimetric Implications of Residual Tracking Errors During Robotic SBRT of Liver Metastases. Int J Radiat Oncol Biol Phys 97(4):839–848CrossRefPubMed
22.
Lacornerie T, Lisbona A, Mirabel X et al (2014) GTV-based prescription in SBRT for lung lesions using advanced dose calculation algorithms. Radiat Oncol 9(16):223CrossRefPubMedPubMedCentral
23.
Schlaefer A, Schweikard A (2008) Stepwise multi-criteria optimization for robotic radiosurgery. Med Phys 35(5):2094–2103CrossRefPubMed
24.
Blanck O, Wang L, Baus W et al (2016) Inverse Treatment Planning for Spinal Robotic Radiosurgery: An International Multi-Institutional Benchmark Trial. J Appl Clin Med Phys 17(3):313–330CrossRefPubMedPubMedCentral
25.
Deng J, Guerrero T, Ma CM et al (2004) Modelling 6 MV photon beams of a stereotactic radiosurgery system for Monte Carlo treatment planning. Phys Med Biol 7;49(9):1689–1704 (May)CrossRef
26.
Grimm J, LaCouture T, Croce R et al (2011) Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy. J Appl Clin Med Phys 12(2):3368–3368 (Review)CrossRefPubMed
27.
Trakul N, Chang CN, Harris J et al (2012) Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. Int J Radiat Oncol Biol Phys 1;84(1):231–237 (Sep)CrossRef
28.
Ernst F, Dürichen R, Schlaefer A, Schweikard A (2013) Evaluating and comparing algorithms for respiratory motion prediction. Phys Med Biol 58(11):3911–3929CrossRefPubMed
29.
Malinowski KT, McAvoy TJ, George R et al (2012) Mitigating errors in external respiratory surrogate-based models of tumor position. Int J Radiat Oncol Biol Phys 82(5):e709–e716CrossRefPubMedPubMedCentral
30.
Bibault JE, Prevost B, Dansin E et al (2012) Image-guided robotic stereotactic radiation therapy with fiducial-free tumor tracking for lung cancer. Radiat Oncol 7(24):102CrossRefPubMedPubMedCentral
31.
Malinowski K, McAvoy TJ, George R et al (2013) Maintaining tumor targeting accuracy in real-time motion compensation systems for respiration-induced tumor motion. Med Phys 40(7):71709CrossRefPubMedPubMedCentral
32.
33.
Ceylan C, Hamacı A, Ayata H et al (2017) Re-Irradiation of Locoregional NSCLC Recurrence Using Robotic Stereotactic Body Radiotherapy. Oncol Res Treat 40(4):207–214CrossRefPubMed
34.
Trovo M, Minatel E, Durofil E et al (2014) Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer. Int J Radiat Oncol Biol Phys 88(5):1114–1119CrossRefPubMed
35.
Giuliani ME, Hope A, Mangona V et al (2017) Predictors and Patterns of Regional Recurrence Following Lung SBRT: A Report From the Elekta Lung Research Group. Clin Lung Cancer 18(2):162–168CrossRefPubMed
36.
Nieder C, De Ruysscher D, Gaspar LE et al (2017) Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease : A multi-institutional treatment recommendation. Strahlenther Onkol. https://​doi.​org/​10.​1007/​s00066-017-1130-0
37.
Bibault JE, Mirabel X, Lacornerie T et al (2015) Adapted Prescription Dose for Monte Carlo Algorithm in Lung SBRT: Clinical Outcome on 205 Patients. PLOS ONE 10(7):e133617CrossRefPubMedPubMedCentral
38.
van der Voort van Zyp NC, Hoogeman MS, van de Water S et al (2010) Clinical introduction of Monte Carlo treatment planning: a different prescription dose for non-small cell lung cancer according to tumor location and size. Radiother Oncol 96(1):55–60CrossRefPubMed
39.
40.
41.
Dewas S, Bibault JE, Mirabel X et al (2012) Prognostic factors affecting local control of hepatic tumors treated by Stereotactic Body Radiation Therapy. Radiat Oncol 7:166CrossRefPubMedPubMedCentral
42.
Chang DT, Swaminath A, Kozak M et al (2011) Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 117(17):4060–4069CrossRefPubMed
43.
Wahl DR, Stenmark MH, Tao Y et al (2016) Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. J Clin Oncol 34(5):452–459CrossRefPubMed
44.
45.
46.
47.
Klement RJ, Allgäuer M, Appold S et al (2014) Support vector machine-based prediction of local tumor control after stereotactic body radiation therapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 88(3):732–738CrossRefPubMed
48.
Klement RJ, Allgäuer M, Andratschke N et al (2016) Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases. Int J Radiat Oncol Biol Phys 94(4):841–849CrossRefPubMed
Metadata
Title
Breathing-motion-compensated robotic guided stereotactic body radiation therapy
Patterns of failure analysis
Authors
Susanne Stera, MD
Panagiotis Balermpas, MD
Mark K. H. Chan, PhD
Stefan Huttenlocher, MD
Stefan Wurster, MD
Christian Keller, MD
Detlef Imhoff
Dirk Rades, MD
Jürgen Dunst, MD
Claus Rödel, MD
Guido Hildebrandt, MD
Oliver Blanck, PhD
Publication date
01-02-2018
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 2/2018
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-017-1204-z

Other articles of this Issue 2/2018

Strahlentherapie und Onkologie 2/2018 Go to the issue

Literatur kommentiert

Langzeitergebnisse der adjuvanten im Vergleich zur Early-Salvage-Bestrahlung beim pT3N0-Prostatakarzinom nach radikaler Prostatektomie

Original Article

Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer

Original Article

Radiotherapy for extramedullary leukaemic manifestation (Chloroma)

Original Article

Radiation-induced liver injury mimicking liver metastases on FDG-PET-CT after chemoradiotherapy for esophageal cancer

Original Article

Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma

Literatur kommentiert

Frühe Mitbetreuung nichtheilbarer Krebspatienten durch Palliativteams bessert die Lebensqualität und fördert Gespräche über Versorgungswünsche am Lebensende